US FDA Sending AZ, Other Cancer Sponsors Trial Design Message With Imfinzi AdComm

 
• By Sarah Karlin-Smith

The Oncologic Drugs Advisory Committee will vote on a product agnostic question related to perioperative trial designs during a 25 July meeting after discussing whether AstraZeneca needs an additional trial for its Imfinzi perioperative regimen in non-small cell lung cancer.

red bullhorn with sign underneath that says "attention please"
The FDA's 25 July ODAC meeting appears important for many sponsors developing immunotherapies. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers